ADMA — ADMA Biologics, Inc.

ADMA Biologics, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $510 million for the full year 2025, up 20% year-over-year.
• Adjusted EBITDA: $231 million, a 40% increase year-over-year.
• Adjusted Net Income: $161 million, reflecting a 35% growth.
• Fourth Quarter Revenue: $139.2 million, an 18% year-over-year increase.
• Fourth Quarter Adjusted EBITDA: $73.6 million, up 52%.
• Fourth Quarter Adjusted Net Income: $52.6 million, a 57% increase.
• Gross Margin: Expanded to 63.8% in Q4 2025, compared to 51.5% in 2024.

2. Strategic Updates and Business Highlights

• Ascentive Performance: Achieved $363 million in net revenue for 2025, a 51% year-over-year growth, with strong prescriber adoption and utilization.
• Manufacturing Improvements: Transition to yield-enhanced production has been integrated into routine operations, supporting gross margin growth.
• Plasma Collection Network: Enhanced capital efficiency through the monetization of three plasma centers while securing long-term high-titer plasma supply agreements.
• Leadership Transition: Brad Tade announced his retirement as CFO, with Terry Kohler appointed as the new CFO, bringing expertise in working capital optimization.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to exceed $635 million.
• 2026 Adjusted Net Income: Projected to exceed $255 million.
• 2026 Adjusted EBITDA: Anticipated to exceed $360 million.
• 2027 Projections: Revenue expected to exceed $775 million, with adjusted net income and EBITDA also forecasted to grow significantly.
• Long-term Potential: SG001 pipeline asset represents a potential $300-$500 million peak annual revenue opportunity.

4. Bad News, Challenges, or Points of Concern

• Working Capital Management: Recent increases in working capital due to revenue growth may affect cash flow; however, improvements are expected as receivables normalize.
• Market Penetration: While Ascentive is performing well, there remains a need for continued penetration into the immunology market, which could present challenges if growth stalls.
• Dependence on Plasma Supply: The company relies heavily on high-titer plasma supply, and any disruptions in sourcing could impact production capabilities.

5. Notable Q&A Insights

• Ascentive's Role in Revenue Growth: Ascentive is expected to continue increasing its share of the product mix, with a current split of approximately 70/30 between Ascentive and Bivigam.
• New Prescriber Engagement: The company is actively targeting 900 immunology sites, with plans to increase the number of prescribers and institutions using Ascentive.
• McKesson Distribution Agreement: Anticipated to enhance revenue and improve working capital dynamics, with expected impacts materializing in the latter half of 2026.
• Third-Party Plasma Supply: Ongoing efforts to secure additional plasma supply are progressing well, with partnerships expected to enhance collection capabilities.

Overall, ADMA Biologics is positioned for strong growth in 2026, supported by its strategic initiatives and robust financial performance, despite some challenges related to working capital and market penetration.